Riskpilot← Back to searchSign inGet full accessDerma Fina AB
ABActiveOrg 5591166813Grev Magnigatan 15 B Lgh 1302Medical specialists activities · NACE 8622Est. 20171 employees
Revenue 2025
SEK 481K
+43% vs 2024
EBITDA margin
90.4%
+62% vs 2024
Equity ratio
59.9%
Financial strength
Net profit 2025
SEK 315K
-34% vs 2024
| Revenue | SEK 481K | +43% |
| EBITDA | SEK 435K | +62% |
| Net profit | SEK 315K | -34% |
| Total assets | SEK 2M | +7% |
| Equity | SEK 1,2M | +10% |
| Employees | 1 | — |
Legal name
Derma Fina AB
Org number
5591166813
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
22 juni 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva service och konsultation inom läkarvård. Därtill ska bolaget erbjuda estetiska behandlingar samt därmed förenliga tjänster.
Address
Grev Magnigatan 15 B Lgh 1302
Email
dermafinaab@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 606 | 351 | 423 | 337 | 481 |
| Staff expenses | — | −26 | −111 | −59 | −31 |
| EBITDA | 219 | 289 | 294 | 269 | 435 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 219 | 289 | 294 | 269 | 435 |
| Net financials | −22 | −25 | −25 | −26 | −29 |
| Profit before tax | 196 | 264 | 270 | 620 | 415 |
| Tax | −42 | −56 | −61 | −146 | −101 |
| Net profit | 154 | 208 | 208 | 474 | 315 |
| Item | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 985 | 1 973 | 2 007 | 1 869 | 1 996 |
| Equity | 786 | 807 | 820 | 1 091 | 1 196 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 672 | 639 | 660 | 628 | 660 |
| Total debt | 672 | 639 | 660 | 628 | 660 |
EBITDA margin
90.4%
This company
15.8%
Market median
+472% vs market
20222025
Equity ratio
59.9%
This company
38.2%
Market median
+57% vs market
20222025
Return on equity
26.3%
This company
18.4%
Market median
+43% vs market
20222025
Net profit margin
65.4%
This company
8.1%
Market median
+707% vs market
20222025
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20222025
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-02-01 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-02-01 – 2022-01-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Derma Fina AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tibor Dzuro | Deputy Board Member | 0 companies |
| Ezio Cristofoli | Deputy Board Member | 0 companies |
| Tibor Dzuro | Deputy Board Member | 0 companies |
| Petra Cristofoli Dzurová | Board of Directors | 0 companies |
| Ezio Cristofoli | Deputy Board Member | 0 companies |